Deallus Consulting is happy to announce its partnership with ArchiMed, Europe’s first independent private equity healthcare specialist.
"The Deallus investment represents an exciting opportunity for us to become more involved in the Pharma Services sector and complements well our European portfolio of growing and innovative Healthcare companies," says Robin Filmer-Wilson, a Managing Partner of ArchiMed.
Deallus was founded in 2004 and is a global consultancy specializing in life sciences; the firm leverages their deep market understanding in life sciences and the pharmaceutical industry to partner with clients and help them develop winning strategies. Throughout its first ten years, Deallus has experienced consistent year-on-year growth, building its brand as a premier life sciences strategy consultancy with an established footprint in the US, Europe and Asian markets.
"We are excited to work in partnership with ArchiMed and leverage their networks in both the consulting and healthcare industries to help take Deallus into the next phase of its growth. With Archimed’s support, we will look to further extend our global footprint and grow our service offering as we continue to develop innovative approaches to help our clients address competitive challenges in an increasingly complex healthcare environment" says Deallus CEO, Claudio D’Ambrosio.
With the investment, ArchiMed will become majority shareholders of Deallus. Founders Richard and Sarah Withers will continue to have a vested interest in Deallus by retaining a stake in equity; other senior members of Deallus have demonstrated commitment to the collaboration with ArchiMed by reinvesting their shares into the expanded group, including co-founder Jonas Pedersen, all members of the executive team and other non-executive partners. The new Board will consist of: Robin Filmer-Wilson (acting as Chairman), Claudio D’Ambrosio, Jonas Pedersen and Non-Executive Directors Christoph Böhmer (an Operating Partner with ArchiMed) and Steve Arlington (a former Managing Partner in PWC’s Pharmaceutical and Life Sciences Division). Richard Withers will continue to remain on the Board for an additional 18 months to ensure a smooth transition into the new partnership.
About ArchiMed - Founded by Managing Partners Denis Ribon, Vincent Guillaumot and Robin Filmer-Wilson, along with several colleagues also from 3i Healthcare team, ArchiMed is the first independent private equity team dedicated to the healthcare sector in Europe. The firm’s inaugural Med 1 fund surpassed its €120 million target, closing on its hard cap of €150 million in June 2015. The team also includes Operating Partner Loïc Kubitza, previously a Leader at PWC’s Healthcare and Life Sciences Practice, and Operating Partner Christoph Böhmer, previously Managing Director of €1 billion-in-revenues cardiovascular leader Biotronik. In the last fifteen years, the ArchiMed team has invested more than €1 billion in 20-plus companies, achieving a total return of over 2.6 times invested capital.
About Deallus - Deallus Consulting is an innovative global life science consultancy. For 11 years it has supported the strategy development process for top 20 pharmaceutical companies, as well as mid-size pharma and biotech companies, by harnessing objective external perspectives with in-depth market knowledge and rigorous analytical capability. Today Deallus has an established footprint in the US, Europe and Asian markets with offices in London, New York, Princeton, Los Angeles, Singapore and Tokyo. The firm leverages their deep market understanding in the life sciences and bio-pharmaceutical, diagnostics and device industries to partner with clients and help them develop winning strategies.
Contacts:
Robin Filmer-Wilson, rfw@archimed-group.eu, +44 (0)7964 237 302
Claudio D’Ambrosio, claudiod@deallusconsulting.com, +1 (646) 553-4280
Deallus Consulting and ArchiMed Close Partnership Agreement
Company: Deallus Consulting
Contact Name: David Oates
Contact Email: david@stalwartcom.com
Contact Name: David Oates
Contact Email: david@stalwartcom.com